Piper Sandler Maintains Bullish $48 Price Target on Avalo Therapeutics (AVTX)

Avalo Therapeutics, Inc. (NASDAQ:AVTX) is one of the top long-term biotechnology stocks to buy. On October 17, Piper Sandler analyst Yasmeen Rahimi reaffirmed her Buy rating on Avalo Therapeutics Inc. (NASDAQ:AVTX), maintaining a price target of $48, which implies a substantial upside potential of 167.86% from the stock’s current trading levels.

The buy stance underscores confidence in Avalo’s strategic direction and pipeline progress as it makes progress in immune dysregulation therapies. The analyst’s optimism comes on the heels of recent leadership changes, strategic collaborations, and clinical pipeline development. Avalo’s focus on novel immunology targets and its ability to execute on development milestones were central to Piper Sandler’s bullish outlook.

Avalo Therapeutics, Inc. (NASDAQ:AVTX) is a biotechnology company focused on developing treatments for immune-mediated inflammatory diseases. Its lead product candidate, AVTX-009, is an anti-IL-1β antibody in a Phase 2 clinical trial for hidradenitis suppurativa (HS). The company’s pipeline also includes other assets, such as quisovalimab and AVTX-008, which are designed to modulate the immune system.

While we acknowledge the potential of AVTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: Billionaire Steve Cohen’s 10 Small-Cap Stock Picks with Huge Upside Potential and Top 9 Credit Services Stocks to Buy as the US Cuts Interest Rates.

Disclosure: None. This article is originally published at Insider Monkey.